Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence - PubMed (original) (raw)
Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence
Maiken Cavling Arendrup et al. PLoS One. 2010.
Abstract
Four sequential Aspergillus fumigatus isolates from a patient with chronic granulomatous disease (CGD) eventually failing azole-echinocandin combination therapy were investigated. The first two isolates (1 and 2) were susceptible to antifungal azoles, but increased itraconazole, voriconazole and posaconazole MICs were found for the last two isolates (3 and 4). Microsatellite typing showed that the 4 isolates were isogenic, suggesting that resistance had been acquired during azole treatment of the patient. An immunocompromised mouse model confirmed that the in vitro resistance corresponded with treatment failure. Mice challenged with the resistant isolate 4 failed to respond to posaconazole therapy, while those infected by susceptible isolate 2 responded. Posaconazole-anidulafungin combination therapy was effective in mice challenged with isolate 4. No mutations were found in the Cyp51A gene of the four isolates. However, expression experiments of the Cyp51A showed that the expression was increased in the resistant isolates, compared to the azole-susceptible isolates. The microscopic morphology of the four isolates was similar, but a clear alteration in radial growth and a significantly reduced growth rate of the resistant isolates on solid and in broth medium was observed compared to isolates 1 and 2 and to unrelated wild-type controls. In the mouse model the virulence of isolates 3 and 4 was reduced compared to the susceptible ones and to wild-type controls. For the first time, the acquisition of azole resistance despite azole-echinocandin combination therapy is described in a CGD patient and the resistance demonstrated to be directly associated with significant change of virulence.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
Figure 1. In vivo susceptibility of sequential A. fumigatus isolates from a CGD patient failing azole therapy.
Susceptibility is shown as survival curve (a and d), as fungal CFU kidney burden (b and e) and as Aspergillus DNA load in kidney tissue. The early susceptible isolate (isolate no 2) is shown in fig. a, b and c and the late resistant isolate (isolate no 4) in fig. c, d and e. AND: anidulafungin, POS: posaconazole, AND+POS: combination therapy of anidulafungin and posaconazole, d4: day 4, d8: day 8, * P<0.05 compared to control.
Figure 2. CYP51A mRNA levels in the 4 sequential A. fumigatus isolates and in a control wild type isolate AZN 8196 (WT) and a tri-azole resistant control isolate with over-expression of the CYP51A gene due to the L98H mutation and promoter tandem repeat.
Figure 3. In vivo virulence of sequential isolates of A. fumigatus in immunosuppressed mice.
Survival of mice in groups of six challenged with each of the four sequential isolates (1–4) or a control isolate (NCPF2109), respectively, is shown. The survival data was combined per isolate, thus each survival curve displays the mortality of six mice challenged with the indicated isolate, two of which were challenged with a high inoculum (5x104 CFU/ml), two with an intermediate inoculum (104 CFU/ml) and two with a low inoculum (2×103 CFU/ml).
Figure 4. Growth rate of the 4 sequential isolates expressed as radial growth rate on solid V8 agar (a) and as optical densities in fluent medium (b).
The laboratory strain NCP2109 is included as unrelated comparator. In the radial growth experiment (a) the growth rate is expressed in mean diameter (mm) and Kr (mm/hour) after 24–72 hours of two separate experiments performed in triplicate. In the kinetic evaluation of growth over time in liquid medium (b) growth is expressed as optical densities measured every 10 min.
Similar articles
- Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands.
van Ingen J, van der Lee HA, Rijs TA, Zoll J, Leenstra T, Melchers WJ, Verweij PE. van Ingen J, et al. J Antimicrob Chemother. 2015 Jan;70(1):178-81. doi: 10.1093/jac/dku364. Epub 2014 Oct 9. J Antimicrob Chemother. 2015. PMID: 25301884 - High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance.
Takeda K, Suzuki J, Watanabe A, Arai T, Koiwa T, Shinfuku K, Narumoto O, Kawashima M, Fukami T, Tamura A, Nagai H, Matsui H, Kamei K. Takeda K, et al. Med Mycol. 2021 Apr 6;59(4):327-334. doi: 10.1093/mmy/myaa052. Med Mycol. 2021. PMID: 32642756 - Surveillance for azole resistance in clinical and environmental isolates of Aspergillus fumigatus in Australia and cyp51A homology modelling of azole-resistant isolates.
Talbot JJ, Subedi S, Halliday CL, Hibbs DE, Lai F, Lopez-Ruiz FJ, Harper L, Park RF, Cuddy WS, Biswas C, Cooley L, Carter D, Sorrell TC, Barrs VR, Chen SC. Talbot JJ, et al. J Antimicrob Chemother. 2018 Sep 1;73(9):2347-2351. doi: 10.1093/jac/dky187. J Antimicrob Chemother. 2018. PMID: 29846581 - Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis?
Snelders E, Melchers WJ, Verweij PE. Snelders E, et al. Future Microbiol. 2011 Mar;6(3):335-47. doi: 10.2217/fmb.11.4. Future Microbiol. 2011. PMID: 21449843 Review.
Cited by
- Fitness Studies of Azole-Resistant Strains of Aspergillus fumigatus.
Valsecchi I, Mellado E, Beau R, Raj S, Latgé JP. Valsecchi I, et al. Antimicrob Agents Chemother. 2015 Dec;59(12):7866-9. doi: 10.1128/AAC.01594-15. Epub 2015 Sep 28. Antimicrob Agents Chemother. 2015. PMID: 26416854 Free PMC article. - Mechanisms of triazole resistance in Aspergillus fumigatus.
Nywening AV, Rybak JM, Rogers PD, Fortwendel JR. Nywening AV, et al. Environ Microbiol. 2020 Dec;22(12):4934-4952. doi: 10.1111/1462-2920.15274. Epub 2020 Oct 21. Environ Microbiol. 2020. PMID: 33047482 Free PMC article. Review. - Clinical and experimental phenotype of azole-resistant Aspergillus fumigatus with a HapE splice site mutation: a case report.
Ito Y, Takazono T, Koga S, Nakano Y, Ashizawa N, Hirayama T, Tashiro M, Saijo T, Yamamoto K, Imamura Y, Miyazaki T, Yanagihara K, Izumikawa K, Mukae H. Ito Y, et al. BMC Infect Dis. 2021 Jun 14;21(1):573. doi: 10.1186/s12879-021-06279-1. BMC Infect Dis. 2021. PMID: 34126952 Free PMC article. - CYP51 Mutations in the Fusarium solani Species Complex: First Clue to Understand the Low Susceptibility to Azoles of the Genus Fusarium.
Vermeulen P, Gruez A, Babin AL, Frippiat JP, Machouart M, Debourgogne A. Vermeulen P, et al. J Fungi (Basel). 2022 May 20;8(5):533. doi: 10.3390/jof8050533. J Fungi (Basel). 2022. PMID: 35628788 Free PMC article. - In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations.
Escribano P, Recio S, Peláez T, González-Rivera M, Bouza E, Guinea J. Escribano P, et al. Antimicrob Agents Chemother. 2012 Jan;56(1):174-8. doi: 10.1128/AAC.00301-11. Epub 2011 Oct 17. Antimicrob Agents Chemother. 2012. PMID: 22006000 Free PMC article.
References
- Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–360. - PubMed
- Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents. 2006;28:450–453. - PubMed
- Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356:1481–1483. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources